Lack of Association between Genetic Polymorphism of CYP11B2 and Hypertension in Japanese: The Suita Study.
スポンサーリンク
概要
- 論文の詳細を見る
Aldosterone synthase (<I>CYP11B2</I>) is a key enzyme in the biosynthesis of aldosterone. Recently, a polymorphism in the 5'-flanking region of the <I>CYP11B2</I> gene [T(−344)C] has been reported to be associated with blood pressure and plasma aldosterone levels. We investigated the association between this polymorphism and hypertension in a large population-based sample of 4,000 Japanese. The genotype distribution in hypertensive subjects (<I>n</I>=1,535) was compared to that in normotensive subjects (<I>n</I>=2,514). In subjects not receiving antihypertensive medication, the influence of the genotype on blood pressure values adjusted for clinical covariates was analyzed. All analyses were performed separately for men and women. The genotype distribution did not differ between hypertensive and normotensive subjects in either men (frequency of C allele: 30.3% vs. 31.4%, <I>p</I>=0.48) or women (31.5% vs. 31.7%, <I>p</I>=0.93). There were no significant differences in systolic blood pressure, diastolic blood pressure, or pulse pressure among the three genotypes in either men or women who had not received hypertensive medication. Our data suggest that the T(−344)C polymorphism of <I>CYP11B2</I> is unlikely to influence blood pressure status in the Japanese population. (Hypertens Res 2001; 24: 105-109)
- 日本高血圧学会の論文
日本高血圧学会 | 論文
- Telmisartan treatment decreases Visceral Fat Accumulation and improves Serum Levels of Adiponectin and Vascular Inflammation Markers in Japanese Hypertensive Patients.
- The Effects of Verapamil SR and Bisoprolol on Reducing the Sympathetic Nervous System's Activity.
- The Role of Renal Dopamine in the Reduction of High Blood Pressure by β1-Selective β-Blocker with Intrinsic Sympathomimetic Activity in Spontaneously Hypertensive Rats
- Effects of Long-Term Antihypertensive Therapy on Physical Fitness of Men with Mild Hypertension.
- Prediction of Progression of Left Ventricular Hypertrophy in Mild Hypertension: 5-Year Observations without Pharmacological Intervention.